These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
147 related articles for article (PubMed ID: 39156484)
21. Impact of CYP2C19 Genotype and Drug Interactions on Voriconazole Plasma Concentrations: A Spain Pharmacogenetic-Pharmacokinetic Prospective Multicenter Study. Blanco-Dorado S; Maroñas O; Latorre-Pellicer A; Rodríguez Jato MT; López-Vizcaíno A; Gómez Márquez A; Bardán García B; Belles Medall D; Barbeito Castiñeiras G; Pérez Del Molino Bernal ML; Campos-Toimil M; Otero Espinar F; Blanco Hortas A; Durán Piñeiro G; Zarra Ferro I; Carracedo Á; Lamas MJ; Fernández-Ferreiro A Pharmacotherapy; 2020 Jan; 40(1):17-25. PubMed ID: 31782536 [TBL] [Abstract][Full Text] [Related]
22. Voriconazole therapeutic drug monitoring in critically ill patients improves efficacy and safety of antifungal therapy. Li H; Li M; Yan J; Gao L; Zhou L; Wang Y; Li Q; Wang J; Chen T; Wang T; Zheng J; Qiang W; Zhang Y; Shi Q Basic Clin Pharmacol Toxicol; 2020 Dec; 127(6):495-504. PubMed ID: 32639669 [TBL] [Abstract][Full Text] [Related]
24. Impact of Obesity on Voriconazole Pharmacokinetics among Pediatric Hematopoietic Cell Transplant Recipients. Takahashi T; Smith AR; Jacobson PA; Fisher J; Rubin NT; Kirstein MN Antimicrob Agents Chemother; 2020 Nov; 64(12):. PubMed ID: 32988816 [TBL] [Abstract][Full Text] [Related]
25. Association of sustained high plasma trough concentration of voriconazole with the incidence of hepatotoxicity. Suzuki Y; Tokimatsu I; Sato Y; Kawasaki K; Sato Y; Goto T; Hashinaga K; Itoh H; Hiramatsu K; Kadota J Clin Chim Acta; 2013 Sep; 424():119-22. PubMed ID: 23747486 [TBL] [Abstract][Full Text] [Related]
26. Voriconazole therapeutic drug monitoring including analysis of CYP2C19 phenotype in immunocompromised pediatric patients with invasive fungal infections. Resztak M; Zalewska P; Wachowiak J; Sobkowiak-Sobierajska A; Główka FK Eur J Clin Pharmacol; 2024 Nov; 80(11):1829-1840. PubMed ID: 39240338 [TBL] [Abstract][Full Text] [Related]
27. Voriconazole therapeutic drug monitoring: Factors associated with supratherapeutic and subtherapeutic voriconazole concentrations. You H; Dong Y; Zou Y; Zhang T; Lei J; Chen L; Wang X; Dong Y; Wang T Int J Clin Pharmacol Ther; 2018 May; 56(5):239-246. PubMed ID: 29393850 [TBL] [Abstract][Full Text] [Related]
28. Effects of antifungal stewardship using therapeutic drug monitoring in voriconazole therapy on the prevention and control of hepatotoxicity and visual symptoms: A multicentre study conducted in Japan. Hamada Y; Ueda T; Miyazaki Y; Nakajima K; Fukunaga K; Miyazaki T; Nakada-Motokawa N; Nagao M; Kawamura H; Shigemi A; Ebihara F; Kimura T; Ikegame K; Uchino M; Ikeuchi H; Takesue Y Mycoses; 2020 Aug; 63(8):779-786. PubMed ID: 32510723 [TBL] [Abstract][Full Text] [Related]
29. A retrospective, multicenter study of voriconazole trough concentrations and safety in patients with Child-Pugh class C cirrhosis. Wang T; Yan M; Tang D; Xue L; Zhang T; Dong Y; Zhu L; Wang X; Dong Y J Clin Pharm Ther; 2018 Dec; 43(6):849-854. PubMed ID: 29893015 [TBL] [Abstract][Full Text] [Related]
30. Voriconazole treatment in adults and children with hematological diseases: can it be used without measurement of plasma concentration? Girmenia C; Annino L; Bertaina A; Mariotti B; Caselli D; Fanci R; Barberi W; Marchesi F; Carotti A; Ferrari A; Cerchiara E; Cupelli L; Arcioni F; Ribersani M; Proia A; Cartoni C; Girardi K; Venditti A; Cassetta MI; Fallani S; Novelli A Med Mycol; 2018 Apr; 56(3):263-278. PubMed ID: 28992093 [TBL] [Abstract][Full Text] [Related]
31. Enhancing the identification of voriconazole-associated hepatotoxicity by targeted metabolomics. Chiang YH; Cheng CN; Chuang PJ; Chen YC; Chen YJ; Kuo CH; Lin SW; Chang LC Int J Antimicrob Agents; 2024 Jan; 63(1):107028. PubMed ID: 37931850 [TBL] [Abstract][Full Text] [Related]
32. Population pharmacokinetic-pharmacodynamic analysis of voriconazole and anidulafungin in adult patients with invasive aspergillosis. Liu P; Mould DR Antimicrob Agents Chemother; 2014 Aug; 58(8):4727-36. PubMed ID: 24914120 [TBL] [Abstract][Full Text] [Related]
33. Population Pharmacokinetics in China: The Dynamics of Intravenous Voriconazole in Critically Ill Patients with Pulmonary Disease. Chen W; Xie H; Liang F; Meng D; Rui J; Yin X; Zhang T; Xiao X; Cai S; Liu X; Li Y Biol Pharm Bull; 2015; 38(7):996-1004. PubMed ID: 26133710 [TBL] [Abstract][Full Text] [Related]
34. Isavuconazole: Case Report and Pharmacokinetic Considerations. Marchesi F; Girmenia C; Goffredo BM; Salvatorelli E; Romano A; Mengarelli A; Minotti G; Menna P Chemotherapy; 2018; 63(5):253-256. PubMed ID: 30458443 [TBL] [Abstract][Full Text] [Related]
35. Prediction of plasma trough concentration of voriconazole in adult patients using machine learning. Cheng L; Zhao Y; Liang Z; You X; Jia C; Liu X; Wang Q; Sun F Eur J Pharm Sci; 2023 Sep; 188():106506. PubMed ID: 37356464 [TBL] [Abstract][Full Text] [Related]
36. [Drug interaction of voriconazole-cyclosporine in children undergoing hematopoietic stem cell transplantation (2013-2014)]. Valenzuela R; Torres JP; Salas C; Gajardo I; Palma J; Catalán P; Santolaya ME; Morales J Rev Chilena Infectol; 2017 Feb; 34(1):14-18. PubMed ID: 28394976 [TBL] [Abstract][Full Text] [Related]
37. Risk factors associated with insufficient and potentially toxic voriconazole plasma concentrations: an observational study. Wei X; Zhao M; Fu P; Xiao X J Chemother; 2019; 31(7-8):401-407. PubMed ID: 31359851 [TBL] [Abstract][Full Text] [Related]
38. Observational Study of Associations between Voriconazole Therapeutic Drug Monitoring, Toxicity, and Outcome in Liver Transplant Patients. Hashemizadeh Z; Badiee P; Malekhoseini SA; Raeisi Shahraki H; Geramizadeh B; Montaseri H Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28923870 [TBL] [Abstract][Full Text] [Related]
39. Longitudinal Analysis of the Effect of Inflammation on Voriconazole Trough Concentrations. Encalada Ventura MA; van Wanrooy MJ; Span LF; Rodgers MG; van den Heuvel ER; Uges DR; van der Werf TS; Kosterink JG; Alffenaar JW Antimicrob Agents Chemother; 2016 May; 60(5):2727-31. PubMed ID: 26883707 [TBL] [Abstract][Full Text] [Related]
40. Trough concentration of voriconazole and its relationship with efficacy and safety: a systematic review and meta-analysis. Jin H; Wang T; Falcione BA; Olsen KM; Chen K; Tang H; Hui J; Zhai S J Antimicrob Chemother; 2016 Jul; 71(7):1772-85. PubMed ID: 26968880 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]